1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Combination Inhalers for Upper Airway Diseases : Products, Markets and Forecasts

Combination Inhalers for Upper Airway Diseases : Products, Markets and Forecasts

  • August 2015
  • ID: 3326172

Summary

Table of Contents

Analyzing the Growth of Dual Therapy Inhalers

Combination inhalers – oral inhalers containing two drugs that complement the therapeutic actions of one another – have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated – Asthma and COPD - both of which are forecast to grow at impressive rates for the remainder of the decade.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

Report Highlights

- Analyzes the market for combination (dual drug) oral inhalers
- Assesses oral inhalation device technology for delivering multiple drugs, and evaluates product technology issues and evolving market factors
- Provides detailed assessments of combination drug inhalers, their growth prospects and market potential
- Evaluates development-stage dual therapy inhalers and assesses likely market entry timelines
- Provides market data and forecasts for dual drug oral inhaler products to 2022
- Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Breo 2017 U.S. PROMOTIONAL AUDIT REPORT

Breo 2017 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • Industry report
  • July 2018
  • by MDDetails

The 5 Key Questions Addressed by this Report:• How many physicians were reached by Breo through reportable promotional activity in 2017 and how does this compare to its peer set in the Asthma and Chronic ...

Qvar 2017 U.S. PROMOTIONAL AUDIT REPORT

Qvar 2017 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • Industry report
  • July 2018
  • by MDDetails

The 5 Key Questions Addressed by this Report:• How many physicians were reached by Qvar through reportable promotional activity in 2017 and how does this compare to its peer set in the Asthma market?• ...

Symbicort 2017 U.S. PROMOTIONAL AUDIT REPORT

Symbicort 2017 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • Industry report
  • July 2018
  • by MDDetails

The 5 Key Questions Addressed by this Report:• How many physicians were reached by Symbicort through reportable promotional activity in 2017 and how does this compare to its peer set in the Asthma and ...

Zosyn - API Insight,2018 $ 500 January 2018

Tracleer - API Insight,2018 $ 500 January 2018

Iressa - API Insight,2018 $ 500 January 2018


Download Unlimited Documents from Trusted Public Sources

Respiratory Disease Statistics and Infectious Disease Statistics in France

  • June 2018
    34 pages
  • Respiratory Dis...  

    Infectious Dise...  

    Therapy  

  • France  

    United States  

    United Kingdom  

View report >

Respiratory Treatment and Opioid Market in Mexico

  • April 2018
    17 pages
  • Respiratory Tre...  

    Opioid  

  • Mexico  

    North America  

View report >

Respiratory Treatment and Thiazolidinedione Market in Australia

  • March 2018
    14 pages
  • Respiratory Tre...  

    Thiazolidinedio...  

    Cytokine  

  • Australia  

    Netherlands  

    United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on